Systemic Sclerosis: Clinical Trials

8 trials for Systemic Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 terminated. 8 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 18Terminated 8
Phase 22Terminated 2

Follow Systemic Sclerosis: new trials by email Literature Review of Systemic Sclerosis trials Research Report on Systemic Sclerosis

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
KYV-101, Standard lymphodepletion regimen - Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous
Phase 1 / Phase 2TerminatedKyverna Therapeutics32024-08-062026-08-31
RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis
RIC alloBMT w PTCy in refractory SSc - Systemic Sclerosis
Phase 1TerminatedSidney Kimmel Comprehensive Cancer Center at Johns Hopkins12022-11-182025-02-04
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell IV Infusion for Systemic Sclerosis
AlloRx - Systemic Sclerosis
Phase 1TerminatedThe Foundation for Orthopaedics and Regenerative Medicine202022-07-042026-10-20
Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Dimethyl Fumarate (DMF), Placebo Oral Tablet - Systemic Sclerosis, Pulmonary; Hypertension
Phase 1TerminatedRobert Lafyatis62016-12-012022-03-17
Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis
UVA1 - Systemic Scleroderma, Systemic Sclerosis
Phase 1 / Phase 2TerminatedNicolas Hunzelmann92008-02-012017-05-31
Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)
Reduced Intensity Allogeneic Transplant, Fludarabine, Busulfan - Systemic Lupus Erythematosus, Systemic Sclerosis
Phase 1TerminatedNew York Medical College12007-08-012014-04-01
Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases
Nonmyeloablative allogeneic stem cell transplant - Systemic Lupus Erythematosus, Systemic Sclerosis
Phase 1TerminatedDuke University42003-01-012016-06-23
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
Fludarabine, Cyclophosphamide, Thymoglobulin - Scleroderma, Systemic Sclerosis
Phase 1TerminatedNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)152002-07-012007-12-28

Narrower conditions

Scleroderma, Systemic (8)  ·  Scleroderma, Diffuse (4)  ·  Autoimmune Diseases (3)  ·  Lupus Erythematosus, Systemic (2)  ·  Hypertension, Pulmonary (1)

Broader conditions

Connective Tissue Diseases (8)  ·  Skin Diseases (8)  ·  Skin and Connective Tissue Diseases (8)  ·  Immune System Diseases (3)  ·  Cardiovascular Diseases (1)  ·  Hypertension (1)  ·  Lung Diseases (1)  ·  Respiratory Tract Diseases (1)  ·  Vascular Diseases (1)

Interventions

fludarabine (3)  ·  Alemtuzumab (2)  ·  Cyclophosphamide (2)  ·  Busulfan (1)  ·  Dimethyl Fumarate (1)  ·  Leukapheresis (1)  ·  Ultraviolet Rays (1)  ·  thymoglobulin (1)

Sponsors

Duke University (1)  ·  Kyverna Therapeutics (1)  ·  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1)  ·  New York Medical College (1)  ·  Nicolas Hunzelmann (1)  ·  Robert Lafyatis (1)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)  ·  The Foundation for Orthopaedics and Regenerative Medicine (1)

Countries

United States (6)  ·  Antigua and Barbuda (1)  ·  Argentina (1)  ·  Germany (1)

Top investigators

Chadwick Prodromos, MD (1)  ·  Cole Sterling, MD (1)  ·  Keith Sullivan, MD (1)  ·  Mitchell Cairo, MD (1)  ·  Nicolas Hunzelmann (1)  ·  Robert A Lafyatis, MD (1)  ·  Robert Herberman, MD (1)